Literature DB >> 31414142

[Challenges in the diagnosis of cartilage tumors : Morphological spectrum and molecular markers].

Wolfgang Hartmann1.   

Abstract

The morphological and clinico-biological spectrum of chondrogenic tumours is wide. Given the diversity of therapeutic approaches, the correctness of the histological diagnosis is of major importance. The aim of this review is to provide insights into the challenges and limitations of diagnostic approaches restricted to morphology and to underscore the importance of an interdisciplinary dialogue between surgeons, radiologists and pathologists. Beyond this, the value of molecular analyses introduced in bone tumor diagnostics in recent years is discussed.

Entities:  

Keywords:  Bone tumors; Chondroblastoma; Chondrosarcoma; Enchondroma; Genetic marker

Mesh:

Substances:

Year:  2019        PMID: 31414142     DOI: 10.1007/s00132-019-03787-6

Source DB:  PubMed          Journal:  Orthopade        ISSN: 0085-4530            Impact factor:   1.087


  14 in total

1.  Incidence, predictive factors, and prognosis of chondrosarcoma in patients with Ollier disease and Maffucci syndrome: an international multicenter study of 161 patients.

Authors:  Suzan H M Verdegaal; Judith V M G Bovée; Twinkal C Pansuriya; Robert J Grimer; Harzem Ozger; Paul C Jutte; Mikel San Julian; David J Biau; Ingrid C M van der Geest; Andreas Leithner; Arne Streitbürger; Frank M Klenke; Francois G Gouin; Domenico A Campanacci; Perrine Marec-Berard; Pancras C W Hogendoorn; Ronald Brand; Antonie H M Taminiau
Journal:  Oncologist       Date:  2011-12-06

2.  GRM1 is upregulated through gene fusion and promoter swapping in chondromyxoid fibroma.

Authors:  Karolin H Nord; Henrik Lilljebjörn; Francesco Vezzi; Jenny Nilsson; Linda Magnusson; Johnbosco Tayebwa; Danielle de Jong; Judith V M G Bovée; Pancras C W Hogendoorn; Karoly Szuhai
Journal:  Nat Genet       Date:  2014-03-23       Impact factor: 38.330

3.  Identification of a novel, recurrent HEY1-NCOA2 fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data.

Authors:  Lu Wang; Toru Motoi; Raya Khanin; Adam Olshen; Fredrik Mertens; Julia Bridge; Paola Dal Cin; Cristina R Antonescu; Samuel Singer; Meera Hameed; Judith V M G Bovee; Pancras C W Hogendoorn; Nicholas Socci; Marc Ladanyi
Journal:  Genes Chromosomes Cancer       Date:  2011-10-27       Impact factor: 5.006

4.  Interobserver reliability in the histopathological diagnosis of cartilaginous tumors in patients with multiple osteochondromas.

Authors:  Carlos E de Andrea; Herman M Kroon; Ron Wolterbeek; Salvatore Romeo; Andrew E Rosenberg; Barry R De Young; Bernadette Liegl; Carrie Y Inwards; Esther Hauben; Edward F McCarthy; Miguel Idoate; Nicholas A Athanasou; Kevin B Jones; Pancras Cw Hogendoorn; Judith V M G Bovée
Journal:  Mod Pathol       Date:  2012-05-04       Impact factor: 7.842

5.  Assessment of interobserver variability and histologic parameters to improve reliability in classification and grading of central cartilaginous tumors.

Authors:  Daniël Eefting; Yvonne M Schrage; Maartje J A Geirnaerdt; Saskia Le Cessie; Anthonie H M Taminiau; Judith V M G Bovée; Pancras C W Hogendoorn
Journal:  Am J Surg Pathol       Date:  2009-01       Impact factor: 6.394

6.  Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone.

Authors:  Sam Behjati; Patrick S Tarpey; Nadège Presneau; Susanne Scheipl; Nischalan Pillay; Peter Van Loo; David C Wedge; Susanna L Cooke; Gunes Gundem; Helen Davies; Serena Nik-Zainal; Sancha Martin; Stuart McLaren; Victoria Goodie; Ben Robinson; Adam Butler; Jon W Teague; Dina Halai; Bhavisha Khatri; Ola Myklebost; Daniel Baumhoer; Gernot Jundt; Rifat Hamoudi; Roberto Tirabosco; M Fernanda Amary; P Andrew Futreal; Michael R Stratton; Peter J Campbell; Adrienne M Flanagan
Journal:  Nat Genet       Date:  2013-10-27       Impact factor: 38.330

7.  The H3F3 K36M mutant antibody is a sensitive and specific marker for the diagnosis of chondroblastoma.

Authors:  M Fernanda Amary; Fitim Berisha; Rafael Mozela; Rebecca Gibbons; Alice Guttridge; Paul O'Donnell; Daniel Baumhoer; Roberto Tirabosco; Adrienne M Flanagan
Journal:  Histopathology       Date:  2016-03-21       Impact factor: 5.087

8.  IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours.

Authors:  M Fernanda Amary; Krisztian Bacsi; Francesca Maggiani; Stephen Damato; Dina Halai; Fitim Berisha; Robin Pollock; Paul O'Donnell; Anita Grigoriadis; Tim Diss; Malihe Eskandarpour; Nadège Presneau; Pancras Cw Hogendoorn; Andrew Futreal; Roberto Tirabosco; Adrienne M Flanagan
Journal:  J Pathol       Date:  2011-05-19       Impact factor: 9.883

9.  Mutation Analysis of H3F3A and H3F3B as a Diagnostic Tool for Giant Cell Tumor of Bone and Chondroblastoma.

Authors:  Arjen H G Cleven; Saskia Höcker; Inge Briaire-de Bruijn; Karoly Szuhai; Anne-Marie Cleton-Jansen; Judith V M G Bovée
Journal:  Am J Surg Pathol       Date:  2015-11       Impact factor: 6.298

10.  Diagnostic tools in the differential diagnosis of giant cell-rich lesions of bone at biopsy.

Authors:  Jan Rehkämper; Konrad Steinestel; Birte Jeiler; Sandra Elges; Elena Hekeler; Sebastian Huss; Jan Sperveslage; Jendrik Hardes; Arne Streitbürger; Georg Gosheger; Eva Wardelmann; Daniel Baumhoer; Marcel Trautmann; Wolfgang Hartmann
Journal:  Oncotarget       Date:  2018-07-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.